
Adding Anagliptin to Insulin and Metformin Enhances T2D Care
TOPLINE: Adding anagliptin, a DPP-4 inhibitor, to ongoing insulin and metformin therapy was well-tolerated and improved glycemic control at 24 weeks in patients with inadequately controlled type 2 diabetes (T2D). METHODOLOGY: Patients with T2D unresponsive …